PCI Pharma Services to build Clinical Supply Centre of Excellence in New England

The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast
To meet the growing clinical supply market demands in New England, PCI Pharma Services has announced it is constructing a new Clinical Centre of Excellence in Bridgewater, Massachusetts.
This investment makes the company the first global CDMO with integrated end-to-end capabilities to build such a centre, which will provide clinical storage, distribution and packaging with a strong focus on cold chain capabilities.
The company says the new 50,000-sq. ft centre will allow it to be closer to clients in the tri-state area and engage with more than 1000 Boston/Cambridge, the nation’s top biopharma cluster.
Brian Keesee, Vice President and General Manager, Global Operations and Supply of Clinical Services, PCI Pharma Services said the centre will also offer biopharmaceutical clients more convenience and efficiencies, as well as combining a "local feel and global capabilities".
“This expansion is part of our larger strategy to serve biopharmaceutical clients by providing a facility that can service their needs within a relatively short driving distance, while adding to our global footprint," added Keesee.
This news comes less than a month after PCI Pharma announced it is acquiring Lyophilization Services New England, a premier CDMO headquartered in Bedford, New Hampshire.
During the last 18 months, PCI has invested significantly in its global clinical sites including San Diego, Rockford, Melbourne and Berlin as part of its global clinical expansion in all services, including investing in new facilities, refrigerators and freezers, increasing capacity, and adding new storage conditions in service to both large and small molecule compounds.

Related News
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance